“We acknowledge there are significant challenges involved in securing reimbursement for innovative medicines in Australia, and our focus in the near term is on enabling private access so patients are not left waiting without options," said Manny Simons, General Manager of Lilly Australia and New Zealand. …
Lilly therapy approved in Australia as first non-covalent BTK inhibitor for common blood cancer
May 5, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 8 May 2026
May 8, 2026 - - Podcast -
Victoria joins state-funded MenB programs as PBAC rejection creates another 'postcode lottery'
May 8, 2026 - - Latest News -
The approaching major change in Australia’s PBS wholesaling arrangements
May 8, 2026 - - Latest News -
Lilly marks 150 years by lighting a new horizon for health at Vivid Sydney
May 8, 2026 - - Latest News -
Stakeholders must act to protect their voice in response to the risk of a manufactured consensus
May 7, 2026 - - Latest News -
Moderna expands support for early career Australian mRNA researchers
May 7, 2026 - - Latest News -
The review is formally over. Why is it restarting?
May 7, 2026 - - Latest News